Sirio Pharma Co Ltd
SZSE:300791
Sirio Pharma Co Ltd
SZSE:300791
Price:
25.41
CNY
-0.63%
Market Closed
Market Cap:
6B
CNY
Income Statement
Earnings Waterfall
Sirio Pharma Co Ltd
Sirio Pharma Co Ltd
|
Revenue
|
4.1B
CNY
|
|
Cost of Revenue
|
-2.9B
CNY
|
|
Gross Profit
|
1.3B
CNY
|
|
Operating Expenses
|
-791.8m
CNY
|
|
Operating Income
|
460.4m
CNY
|
|
Other Expenses
|
-124.7m
CNY
|
|
Net Income
|
335.7m
CNY
|
Income Statement
Sirio Pharma Co Ltd
Sirio Pharma Co Ltd
Currency: CNY
Millions
TTM
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||
| Revenue |
1 642
N/A
|
1 625
-1%
|
1 580
-3%
|
1 554
-2%
|
1 710
+10%
|
1 866
+9%
|
2 067
+11%
|
2 216
+7%
|
2 316
+5%
|
2 362
+2%
|
2 369
+0%
|
2 283
-4%
|
2 315
+1%
|
2 409
+4%
|
2 507
+4%
|
2 788
+11%
|
2 941
+5%
|
3 222
+10%
|
3 582
+11%
|
3 831
+7%
|
4 028
+5%
|
4 128
+2%
|
|
| Gross Profit | |||||||||||||||||||||||
| Cost of Revenue |
(1 091)
|
(1 082)
|
(1 064)
|
(1 046)
|
(1 151)
|
(1 259)
|
(1 396)
|
(1 499)
|
(1 564)
|
(1 601)
|
(1 596)
|
(1 583)
|
(1 604)
|
(1 680)
|
(1 731)
|
(1 947)
|
(2 076)
|
(2 261)
|
(2 498)
|
(2 675)
|
(2 787)
|
(2 875)
|
|
| Gross Profit |
551
N/A
|
543
-1%
|
516
-5%
|
508
-1%
|
560
+10%
|
607
+8%
|
671
+11%
|
717
+7%
|
752
+5%
|
761
+1%
|
773
+2%
|
699
-10%
|
711
+2%
|
729
+3%
|
777
+7%
|
841
+8%
|
864
+3%
|
961
+11%
|
1 085
+13%
|
1 156
+7%
|
1 241
+7%
|
1 252
+1%
|
|
| Operating Income | |||||||||||||||||||||||
| Operating Expenses |
(312)
|
(327)
|
(356)
|
(341)
|
(360)
|
(368)
|
(361)
|
(399)
|
(414)
|
(427)
|
(483)
|
(459)
|
(477)
|
(492)
|
(528)
|
(578)
|
(609)
|
(663)
|
(696)
|
(711)
|
(765)
|
(792)
|
|
| Selling, General & Administrative |
(245)
|
(254)
|
(281)
|
(290)
|
(318)
|
(332)
|
(312)
|
(345)
|
(347)
|
(359)
|
(380)
|
(385)
|
(404)
|
(416)
|
(341)
|
(491)
|
(522)
|
(570)
|
(602)
|
(665)
|
(709)
|
(732)
|
|
| Research & Development |
(67)
|
(66)
|
(62)
|
(62)
|
(66)
|
(68)
|
(62)
|
(71)
|
(74)
|
(74)
|
(77)
|
(84)
|
(82)
|
(85)
|
(70)
|
(84)
|
(88)
|
(95)
|
(97)
|
(119)
|
(131)
|
(134)
|
|
| Depreciation & Amortization |
0
|
0
|
(18)
|
0
|
0
|
0
|
(24)
|
0
|
0
|
0
|
(35)
|
0
|
0
|
0
|
(123)
|
0
|
0
|
0
|
(67)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
(7)
|
7
|
12
|
24
|
32
|
36
|
18
|
7
|
6
|
10
|
10
|
9
|
8
|
6
|
(2)
|
1
|
3
|
71
|
73
|
75
|
74
|
|
| Operating Income |
239
N/A
|
216
-10%
|
160
-26%
|
167
+5%
|
200
+20%
|
239
+19%
|
310
+30%
|
318
+3%
|
338
+7%
|
333
-2%
|
291
-13%
|
240
-17%
|
234
-3%
|
237
+1%
|
249
+5%
|
264
+6%
|
255
-3%
|
298
+17%
|
389
+30%
|
445
+15%
|
476
+7%
|
460
-3%
|
|
| Pre-Tax Income | |||||||||||||||||||||||
| Interest Income Expense |
(13)
|
(15)
|
(8)
|
1
|
14
|
10
|
6
|
13
|
(3)
|
(4)
|
(1)
|
(5)
|
13
|
25
|
16
|
9
|
(18)
|
(46)
|
(107)
|
(116)
|
(124)
|
(129)
|
|
| Non-Reccuring Items |
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
(1)
|
(2)
|
0
|
0
|
1
|
(6)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
4
|
4
|
6
|
7
|
(2)
|
(2)
|
(2)
|
(8)
|
(2)
|
(8)
|
(7)
|
(7)
|
(12)
|
(9)
|
(8)
|
(14)
|
(8)
|
(7)
|
(9)
|
(12)
|
(13)
|
(13)
|
|
| Pre-Tax Income |
230
N/A
|
205
-11%
|
157
-24%
|
175
+12%
|
212
+21%
|
247
+17%
|
312
+26%
|
323
+4%
|
334
+3%
|
320
-4%
|
281
-12%
|
229
-19%
|
234
+2%
|
254
+8%
|
252
-1%
|
259
+3%
|
229
-11%
|
246
+7%
|
273
+11%
|
318
+16%
|
339
+7%
|
318
-6%
|
|
| Net Income | |||||||||||||||||||||||
| Tax Provision |
(20)
|
(19)
|
(14)
|
(19)
|
(34)
|
(38)
|
(55)
|
(59)
|
(55)
|
(49)
|
(49)
|
(40)
|
(38)
|
(46)
|
(39)
|
(42)
|
(47)
|
(50)
|
(33)
|
(42)
|
(42)
|
(25)
|
|
| Income from Continuing Operations |
210
|
187
|
143
|
156
|
178
|
209
|
257
|
265
|
279
|
272
|
232
|
189
|
196
|
208
|
212
|
216
|
182
|
196
|
240
|
275
|
296
|
293
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
21
|
25
|
41
|
39
|
38
|
42
|
|
| Net Income (Common) |
210
N/A
|
187
-11%
|
143
-24%
|
156
+9%
|
178
+14%
|
209
+17%
|
257
+23%
|
265
+3%
|
279
+5%
|
272
-3%
|
232
-15%
|
189
-18%
|
196
+4%
|
208
+6%
|
212
+2%
|
227
+7%
|
204
-10%
|
221
+9%
|
281
+27%
|
315
+12%
|
334
+6%
|
336
+0%
|
|
| EPS (Diluted) |
1.55
N/A
|
1.38
-11%
|
0.97
-30%
|
0.86
-11%
|
0.99
+15%
|
1.16
+17%
|
1.43
+23%
|
1.47
+3%
|
1.55
+5%
|
1.51
-3%
|
0.94
-38%
|
1.02
+9%
|
1.03
+1%
|
1.13
+10%
|
0.9
-20%
|
1.25
+39%
|
1.12
-10%
|
1.23
+10%
|
1.2
-2%
|
1.34
+12%
|
1.4
+4%
|
1.43
+2%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
